Translate Bio Stock Forecast, Price & News

0.00 (0.00 %)
(As of 09/14/2021)
Today's Range
50-Day Range
52-Week Range
Volume34,832 shs
Average Volume1.66 million shs
Market Capitalization$2.82 billion
P/E Ratio66.71
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive TBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for Translate Bio and its competitors with MarketBeat's FREE daily newsletter.

Translate Bio logo

About Translate Bio

Precipio, a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. Its products include ICP, HemeScreen, and IV-Cell, and services include primary diagnostic, SmartPath, SmartGen, HemeScreen Panel, and ICE COLD-PCR. The company was founded on March 6, 1997 and is headquartered in New Haven, CT.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.42 out of 5 stars

Medical Sector

1077th out of 1,352 stocks

Biological Products, Except Diagnostic Industry

162nd out of 193 stocks

Analyst Opinion: 1.1Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Translate Bio (NASDAQ:TBIO) Frequently Asked Questions

Is Translate Bio a buy right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Translate Bio in the last year. There are currently 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Translate Bio stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TBIO, but not buy additional shares or sell existing shares.
View analyst ratings for Translate Bio
or view top-rated stocks.

What stocks does MarketBeat like better than Translate Bio?

Wall Street analysts have given Translate Bio a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Translate Bio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Translate Bio?

Translate Bio saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 4,290,000 shares, an increase of 43.5% from the August 15th total of 2,990,000 shares. Based on an average daily trading volume, of 2,670,000 shares, the short-interest ratio is presently 1.6 days. Approximately 6.4% of the shares of the stock are sold short.
View Translate Bio's Short Interest

When is Translate Bio's next earnings date?

Translate Bio is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Translate Bio

How were Translate Bio's earnings last quarter?

Translate Bio, Inc. (NASDAQ:TBIO) released its earnings results on Wednesday, August, 4th. The company reported $0.21 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.23) by $0.44. The business had revenue of $72.65 million for the quarter, compared to the consensus estimate of $38.23 million. Translate Bio had a trailing twelve-month return on equity of 1.50% and a net margin of 17.97%.
View Translate Bio's earnings history

How has Translate Bio's stock been impacted by Coronavirus (COVID-19)?

Translate Bio's stock was trading at $7.43 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TBIO shares have increased by 402.8% and is now trading at $37.36.
View which stocks have been most impacted by COVID-19

What price target have analysts set for TBIO?

9 equities research analysts have issued twelve-month target prices for Translate Bio's shares. Their forecasts range from $19.00 to $38.00. On average, they anticipate Translate Bio's share price to reach $26.29 in the next year. This suggests that the stock has a possible downside of 29.6%.
View analysts' price targets for Translate Bio
or view top-rated stocks among Wall Street analysts.

Who are Translate Bio's key executives?

Translate Bio's management team includes the following people:
  • Ilan Danieli, Chief Executive Officer & Director
  • Ahmed Zaki Sabet, Chief Operating Officer
  • Carl R. Iberger, Chief Financial Officer
  • Ayman A. Mohamed, Vice President-Research & Development
  • Ori Karev, Chief Strategy Officer

What is Craig J. Tuttle's approval rating as Translate Bio's CEO?

13 employees have rated Translate Bio CEO Craig J. Tuttle on Craig J. Tuttle has an approval rating of 5% among Translate Bio's employees. This puts Craig J. Tuttle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Translate Bio's key competitors?

What other stocks do shareholders of Translate Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Translate Bio investors own include Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE), Moderna (MRNA), Johnson & Johnson (JNJ), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and VBI Vaccines (vbiv).

When did Translate Bio IPO?

(TBIO) raised $100 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 7,700,000 shares at $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI served as the underwriters for the IPO.

What is Translate Bio's stock symbol?

Translate Bio trades on the NASDAQ under the ticker symbol "TBIO."

Who are Translate Bio's major shareholders?

Translate Bio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (14.15%), BlackRock Inc. (7.38%), Vanguard Group Inc. (5.08%), Federated Hermes Inc. (4.95%), State Street Corp (4.54%) and Frazier Management LLC (2.77%). Company insiders that own Translate Bio stock include Baupost Group Llc/Ma, Human Genetic Therapies Shire, Jean Francois Formela, Owen Hughes, Paul D Burgess, Ronald C Renaud, Jr and Sanofi.
View institutional ownership trends for Translate Bio

Which institutional investors are selling Translate Bio stock?

TBIO stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Goldman Sachs Group Inc., Ikarian Capital LLC, Millennium Management LLC, Nuveen Asset Management LLC, First Trust Advisors LP, BlackRock Inc., and Allianz Asset Management GmbH. Company insiders that have sold Translate Bio company stock in the last year include Jean Francois Formela, Owen Hughes, Paul D Burgess, and Ronald C Renaud, Jr.
View insider buying and selling activity for Translate Bio
or view top insider-selling stocks.

Which institutional investors are buying Translate Bio stock?

TBIO stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, JPMorgan Chase & Co., Morgan Stanley, Morgan Stanley, Senvest Management LLC, Vanguard Group Inc., State Street Corp, and Marshall Wace LLP. Company insiders that have bought Translate Bio stock in the last two years include Baupost Group Llc/Ma, and Sanofi.
View insider buying and selling activity for Translate Bio
or or view top insider-buying stocks.

How do I buy shares of Translate Bio?

Shares of TBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Translate Bio's stock price today?

One share of TBIO stock can currently be purchased for approximately $37.36.

How much money does Translate Bio make?

Translate Bio has a market capitalization of $2.82 billion and generates $138.81 million in revenue each year. The company earns $-53,790,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis.

How many employees does Translate Bio have?

Translate Bio employs 122 workers across the globe.

What is Translate Bio's official website?

The official website for Translate Bio is

Where are Translate Bio's headquarters?

Translate Bio is headquartered at 29 HARTWELL AVENUE, LEXINGTON MA, 02421.

How can I contact Translate Bio?

Translate Bio's mailing address is 29 HARTWELL AVENUE, LEXINGTON MA, 02421. The company can be reached via phone at (203) 787-7888.

This page was last updated on 9/21/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.